Free Trial
→ White House to reset Social Security? (From Altimetry) (Ad)
CVE:MPH

Medicure 5/26/2023 Earnings Report

Medicure logo
C$1.06 +0.12 (+12.77%)
As of 05/28/2025 10:09 AM Eastern
ProfileEarnings History

Medicure EPS Results

Actual EPS
C$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$5.63 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Date
5/26/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Medicure Earnings Headlines

Earnings call transcript: Medicure reports Q1 2025 decline in revenue, steady stock
May 24, 2025 | uk.investing.com
Medicure, Inc.: Medicure Announces Closing of Purchase Agreement for the Acquisition of Gateway Medical Pharmacy
March 11, 2025 | finanznachrichten.de
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
May 29, 2025 | Altimetry (Ad)
Tyreek Hill was driving an estimated 60 mph in a 40 mph zone before hectic detainment incident
September 12, 2024 | nypost.com
Medicure Inc. (NGQ1.F)
August 21, 2024 | uk.finance.yahoo.com
Medicure Inc. (MPH.V)
August 12, 2024 | ca.finance.yahoo.com
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (CVE:MPH), a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

View Medicure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles